← Statins × cardiovascular events

SynthesisDrugs2012

Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis.

Folgerdiena M de Vries et al.PubMed ↗Publisher ↗

What the trial testedas reported · 10,187 people · 2012

Not counted

Reduced cardiovascular events

−25%−33% to −15%

Bigger than 6 in 10 for cardiovascular events

As reported

RR 0.75, 95% CI 0.67–0.85

Not counted

Reduced cardiovascular events

−31%−49% to −8%

Bigger than 7 in 10 for cardiovascular events

As reported

RR 0.69, 95% CI 0.51–0.92

Not counted

Reduced cardiovascular events

−30%−46% to −10%

Bigger than 7 in 10 for cardiovascular events

As reported

RR 0.70, 95% CI 0.54–0.90

Range includes no effect

No clear effect on cardiovascular events

−16%−35% to +9%

Bigger than 3 in 10 for cardiovascular events

As reported

RR 0.84, 95% CI 0.65–1.09

Four numbers in the abstract

the abstract, start to end

… or cerebrovascular events (RR 0.75, 95% CI 0.67-0.85), fatal/non-fatal stroke (RR 0.69, 95% CI 0.51-0.92) and fatal/non-fatal myocardial infarction (RR 0.70, 95% CI 0.54-0.90) and a non-significant RR reduction in all-cause mortality (RR 0.84, 95% CI 0.65-1.09).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
RR 0.750.67–0.85
Cardiovascular events
RR 0.690.51–0.92
Cardiovascular events
RR 0.700.54–0.90
Cardiovascular events
RR 0.840.65–1.09
StatinsCardiovascular events
1 / 3

47 papers cite it

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it

The trial

NCT06676683300 enrolled2024
Full record →Abstract, authors, funding and every citing paper · PMID 23186103